Apogee Therapeutics has started a clinical trial for its drug APG333, targeting asthma and COPD, with 32 healthy volunteers expected to participate, and interim results anticipated in late 2025.
AI Assistant
APOGEE THERAPEUTICS INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.